ASCLETIS-B (01672): First-in-Class FASN Inhibitor Denifanstat (ASC40) NDA for Acne Treatment Accepted by China NMPA

Stock News12-10

ASCLETIS-B (01672) announced that the New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, once-daily oral small-molecule fatty acid synthase (FASN) inhibitor targeting moderate-to-severe acne vulgaris, has been accepted by China's National Medical Products Administration (NMPA).

"This NDA acceptance marks a significant milestone in our mission to deliver a potentially groundbreaking therapy for moderate-to-severe acne," said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. "We are excited that denifanstat (ASC40) is now one step closer to commercialization."

ASCLETIS-B has completed Phase II (NCT05104125) and Phase III (NCT06192264) clinical trials for denifanstat (ASC40) in treating moderate-to-severe acne vulgaris. In the Phase III study, denifanstat (ASC40) met all primary, key secondary, and secondary efficacy endpoints (intent-to-treat, ITT analysis), demonstrating significant improvement over placebo. The drug also exhibited a favorable safety and tolerability profile, with all treatment-emergent adverse events (TEAEs) being mild (Grade 1) or moderate (Grade 2). No Grade 3 or 4 TEAEs, serious adverse events (SAEs), or treatment discontinuations related to denifanstat (ASC40) were observed.

On September 17, 2025, ASCLETIS-B presented the Phase III results orally at the European Academy of Dermatology and Venereology (EADV) Annual Congress in Paris, France. The company recently completed pre-NDA discussions with the NMPA and received positive feedback.

ASCLETIS-B holds exclusive rights to develop and commercialize denifanstat (ASC40) in Greater China under a licensing agreement with Sagimet Biosciences Inc. (NASDAQ: SGMT).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment